U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H22ClN5O3
Molecular Weight 451.905
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BETRIXABAN

SMILES

COC1=CC(C(=O)NC2=CC=C(Cl)C=N2)=C(NC(=O)C3=CC=C(C=C3)C(=N)N(C)C)C=C1

InChI

InChIKey=XHOLNRLADUSQLD-UHFFFAOYSA-N
InChI=1S/C23H22ClN5O3/c1-29(2)21(25)14-4-6-15(7-5-14)22(30)27-19-10-9-17(32-3)12-18(19)23(31)28-20-11-8-16(24)13-26-20/h4-13,25H,1-3H3,(H,27,30)(H,26,28,31)

HIDE SMILES / InChI

Description

Betrixaban is an anticoagulant drug which acts as a direct factor Xa inhibitor. Betrixaban is now being developed by Portola Pharmaceuticals. Oral, once-daily Factor Xa inhibitor anticoagulant that directly inhibits the activity of Factor Xa, an important validated target in the blood coagulation pathway, to prevent life-threatening thrombosis. U.S. Food and Drug Administration granted Fast Track designation to betrixaban for extended-duration prevention of venous thromboembolism (VTE; blood clots) in acute medically ill patients (i.e., those who are hospitalized for serious medical conditions, such as heart failure, stroke, infection and pulmonary disease). Has the potential to become the first oral Factor Xa inhibitor anticoagulant approved for hospital-to-home prevention of VTE in acute medically ill patients.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
4.5 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
BEVYXXA
Preventing
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
23.2 ng/mL
40 mg 2 times / day multiple, oral
BETRIXABAN plasma
Homo sapiens
73.1 ng/mL
80 mg 2 times / day multiple, oral
BETRIXABAN plasma
Homo sapiens
122 ng/mL
120 mg 2 times / day multiple, oral
BETRIXABAN plasma
Homo sapiens
38 ng/mL
80 mg single, oral
BETRIXABAN plasma
Homo sapiens
58.2 ng/mL
120 mg single, oral
BETRIXABAN plasma
Homo sapiens
9.37 ng/mL
40 mg single, oral
BETRIXABAN plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
179 ng × h/mL
40 mg 2 times / day multiple, oral
BETRIXABAN plasma
Homo sapiens
488 ng × h/mL
80 mg 2 times / day multiple, oral
BETRIXABAN plasma
Homo sapiens
821 ng × h/mL
120 mg 2 times / day multiple, oral
BETRIXABAN plasma
Homo sapiens
393 ng × h/mL
80 mg single, oral
BETRIXABAN plasma
Homo sapiens
600 ng × h/mL
120 mg single, oral
BETRIXABAN plasma
Homo sapiens
83.1 ng × h/mL
40 mg single, oral
BETRIXABAN plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
39.7 h
40 mg 2 times / day multiple, oral
BETRIXABAN plasma
Homo sapiens
37.3 h
80 mg 2 times / day multiple, oral
BETRIXABAN plasma
Homo sapiens
35.9 h
120 mg 2 times / day multiple, oral
BETRIXABAN plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
40%
40 mg single, oral
BETRIXABAN plasma
Homo sapiens

Doses

AEs

Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
80 mg PO QD for 35 day + 7 days.
Route of Administration: Oral
In Vitro Use Guide
In a tissue factor-induced thrombin-generation assay, betrixaban, in concentrations ranging between 5 and 25 ng/ml, inhibited thrombin generation to trough and peak levels comparable to those achieved by 2.5 mg of fondaparinux.